A multicentre, randomised, double-blind, parallel group comparison of nifedipine GITS 20 mg (Adalat ® LA) once daily and bendrofluazide 2.5 mg once daily in patients with mild-to-moderate hypertension was conducted. Two hundred patients with a diastolic blood pressure (BP) in the range 95 to 109 mm Hg were randomised to active treatment for 6 weeks. For the per-protocol efficacy population, both treatments resulted in clinically significant mean reductions of trough diastolic BP (nifedipine GITS −8.9 mm Hg, bendrofluazide −7.9 mm Hg) and systolic BP (nifedipine GITS −10.4 mm Hg, bendrofluazide −10.5 mm Hg). The study demonstrated that nifedipine GITS was 'at least equivalent' to bendrofluazide in the reduction of trough diastolic BP (onesided upper 95% confidence limit, 0.5 mm Hg), where inequivalence had been pre-defined as a difference in
Introduction
Thiazide diuretics and calcium antagonists are widely used as first-line agents in the treatment of mild-to-moderate hypertension.
In recent years the prescribed doses of thiazides have tended to decrease, which have improved their tolerability and decreased the incidence of adverse metabolic effects seen with the higher doses, whilst efficacy has been maintained.
Nifedipine is a dihydropyridine calcium antagonist which inhibits the influx of calcium ions into the smooth muscle cells of the peripheral resistance vessels, coronary arteries and myocardium. It is widely used as an antihypertensive agent.
Early formulations were required to be administered three times daily. As the formulations have become more refined, so the dosing frequency has been reduced to once daily. One method of achieving this has been the utilization of the GITS mean diastolic BP of у5 mm Hg. Both drugs were well tolerated, the overall incidence of adverse events in the nifedipine GITS treatment group being 34.0% (34/100) and in the bendrofluazide treatment group being 29.0% (29/100). The commonest events (incidence у5%) were headache, constipation, 'flu syndrome and vasodilatation with nifedipine GITS and headache and nausea with bendrofluazide. An increased incidence of elevations of plasma urea and glucose was observed in patients treated with bendrofluazide (9.6% and 30.4% respectively) compared to those treated with nifedipine GITS (3.1% and 18.8% respectively). Nifedipine GITS 20 mg once daily is 'at least equivalent' to bendrofluazide 2.5 mg once daily in reduction of blood pressure in patients with mildto-moderate hypertension.
(Gastrointestinal Therapeutic System) or OROS ® (Oral Retard Osmotic System) system. This relies upon an osmotic pump mechanism which releases the drug at a controlled rate through the gastrointestinal tract, such that nifedipine plasma levels are maintained at a nearly constant level over 24 hours.
A 20 mg formulation of nifedipine GITS has been developed. On the basis of pharmacokinetic data, the nifedipine GITS 20 mg tablet is bioequivalent and dose-proportional to the currently licensed nifedipine GITS tablets (30 mg and 60 mg). It was anticipated that the 20 mg formulation would decrease the incidence of transient side effects, whilst maintaining antihypertensive effect in patients with mild-to-moderate hypertension. A recent study comparing nifedipine GITS 20 mg and placebo in such patients, demonstrated a reduction in trough diastolic blood pressure (BP) of 8.6 mm Hg with similar tolerability to placebo. 1 The present study was conducted in order to examine the antihypertensive effects of nifedipine GITS 20 mg once daily, in comparison to bendrofluazide 2.5 mg once daily, in patients with mildto-moderate hypertension, as well as to assess their safety and tolerability.
Materials and methods
This was a multicentre, randomised, double-blind, parallel group comparison of nifedipine GITS 20 mg once daily and bendrofluazide 2.5 mg once daily in patients with mild-to-moderate hypertension. BP was recorded in the supine position, using a standard mercury sphygmomanometer. For diastolic BP, Korotkoff Phase V was used. If sounds continued to 0 mm Hg Phase IV was used instead.
The total study duration was 8 weeks, comprising a 2-week placebo run-in period followed by 6 weeks active treatment. The study was carried out at 18 general practitioner's clinics in Scotland. The study was approved by the appropriate Local Research Ethical Committees and conducted in accordance with Good Clinical Practice guidelines as issued by the European Commission (July 1990).
Patient population
Male or female patients, who had given informed consent, between the ages of 55 and 80 years inclusive, with mild-to-moderate essential hypertension who had a supine diastolic BP, measured after 5 min rest (using Korotkoff phase V), within the range of 95-109 mm Hg were eligible to enter the study. Supine diastolic BP must also have been 95-109 mm Hg at the end of the placebo run-in to allow randomisation. Supine systolic BP must have been less than 180 mm Hg on both occasions.
Exclusion criteria were applied in order to ensure that only patients for whom it was safe to receive either study drug were included. These included a history of a cardiovascular or cerebrovascular ischaemic event (myocardial infarction, unstable angina pectoris, stroke or transient ischaemic attack) in the previous 3 months, clinically relevant pathologies, pregnancy, lactation or child-bearing potential (even if using contraception), known hypersensitivity to nifedipine or other dihydropyridines or bendrofluazide or other thiazides, concomitant treatment with any other antihypertensive medication in the 2 weeks prior to the study, uncorrected hypokalaemia (potassium Ͻ3.5 mmol/l), significant renal or hepatic dysfunction or concomitant treatment with cimetidine, quinidine, rifampicin or digoxin in the preceding 3 weeks and during the study. In addition, no vasoactive medication was to be taken during the study period.
Treatment schedule
Patients initially underwent a placebo run-in period of 2 weeks duration. Those patients whose diastolic BP was within the specified range of 95-109 mm Hg were then randomised to active treatment for 6 weeks. The two treatment regimens were nifedipine GITS 20 mg once daily and bendrofluazide 2.5 mg once daily, with matching placebos to maintain double-blind.
Efficacy analysis
The primary efficacy parameter was the change from baseline to end of 6 weeks treatment in trough diastolic BP. Baseline was defined as the trough measurement at the end of the placebo run-in period. Patients were included in the per-protocol efficacy analysis if they completed the active treatment period, had tablet compliance in the range 70-130%, had their BP recorded between 23.5 and 25.5 hours after their last dose of medication and took no other vasoactive medication during the study. All patients having baseline and post-randomisation measurement of the primary efficacy parameter were included in an intention-to-treat (ITT) analysis of efficacy on a last-observation-carried-forward basis. Additional secondary efficacy parameters were change from baseline in trough systolic BP and heart rate.
Safety analysis
Clinical safety was monitored by non-directional questioning at each visit for the occurrence of adverse events, pre-and post-treatment physical examinations and laboratory safety screens. The latter were carried out at a central laboratory and included a full blood count with differential, serum chemistry and dipstick urinalysis.
Statistical methodology
The sample size was based on trough diastolic BP, and calculated as follows. The one-sided type I error rate ('significance level') was set at 5% where nifedipine GITS was inferior to bendrofluazide by 5 mm Hg. The type II error rate was set at 20% (ie, power of 80%) where nifedipine GITS was inferior to bendrofluazide by 2 mm Hg. Assuming a standard deviation of 7.5 mm Hg, 79 evaluable patients were required per treatment group. The planned sample size was increased by 15% to 91 patients per treatment group, to take into account invalid patients and the multicentre design increasing the variability. We would conclude that nifedipine GITS would be at least equivalent to bendrofluazide if the one-sided upper 95% confidence limit of the difference in mean trough diastolic BP between the two drugs was less than 5 mm Hg.
One hundred and sixty-seven patients (86 in the nifedipine GITS group and 81 in the bendrofluazide group, combined s.d. 6.4 mm Hg) and 198 patients (100 in the nifedipine GITS group and 98 in the bendrofluazide group, combined s.d. 6.4 mm Hg) were valid for per-protocol and ITT efficacy analyses respectively.
Data and residuals were tested for normality using the Shapiro-Wilk test. Variables were summarised accordingly; if approximately normally distributed using mean and s.d. or standard error (s.e.), if nonnormally distributed using median and interquartile range, if categorical using frequency counts.
At baseline treatment groups were tested for comparability, if approximately normally distributed using Student's two-sample t-test, if non-normally distributed using Wilcoxon two-sample test, if categorical using Mantel-Haenszel chi-square test.
For the efficacy parameters, change from baseline to end of treatment, were analysed using analysis of covariance (ANCOVA) including centre effect and the baseline value of that efficacy parameter. Adjusted means and one-sided upper 95% confidence limits were calculated from the ANCOVA model. Safety analyses; adverse events and laboratory data were summarised using frequency counts. No statistical significance tests were performed on these data.
Results
The 18 clinical centres participating in the study enrolled 228 patients. Twenty-eight patients were not randomised. The reasons for withdrawal prior to randomisation were 'adverse event' (five patients), 'non-compliance' (one patient), 'consent withdrawn' (two patients), 'protocol violation' (22 patients) and 'admission to hospital' (one patient)-patients may have had more than one reason for withdrawal. Two hundred patients (100 in each treatment group) were therefore randomised to double-blind treatment, all of whom received active medication and were included in the safety analysis. Of these, 100 in the nifedipine GITS treatment group and 98 (two patients had no efficacy data on active treatment) in the bendrofluazide treatment group were valid for ITT efficacy. A further 31 patients were excluded from the per-protocol analysis of efficacy, resulting in 167 patients in this population (86 in the nifedipine GITS group and 81 in the bendrofluazide group)-20 patients did not have a trough BP assessment within the 23.5-25.5 h post-dose window, nine patients withdrew from treatment and two patients took prohibited concomitant medication.
Demographic and baseline data for patients valid for safety are summarised in Table 1 . There were no statistically significant (P Ͼ 0.05) differences in any demographic features between treatment groups. Findings for the efficacy populations were very similar. Table 2 summarises, for the per-protocol efficacy population, the mean BP and heart rate at baseline and the changes achieved with both treatments. Both treatments resulted in clinically significant reductions in both mean diastolic (nifedipine GITS −8.9 mm Hg, bendrofluazide −7.9 mm Hg) and systolic (nifedipine GITS −10.4 mm Hg, bendrofluazide −10.5 mm Hg) BP. The observed difference (bendrofluazide minus nifedipine GITS) in change from baseline for diastolic and systolic BP, and the mean and one-sided upper 95% confidence limit of the difference between the treatments, is also shown in Table 2 .
The study was designed to show that nifedipine GITS was 'at least equivalent' to bendrofluazide in reduction of trough diastolic BP, if the one-sided upper 95% confidence limit was less than 5 mm Hg. The one-sided upper 95% confidence limit in diastolic BP was 0.5 mm Hg and thus it can be concluded that nifedipine GITS 20 mg once daily is 'at least equivalent' to bendrofluazide 2.5 mg once daily on trough diastolic BP.
No acceptance ranges for systolic BP and heart rate were predefined. However, the mean differences between the two treatment groups were close to zero, with upper 95% confidence limits of 3.0 mm Hg and 2.1 beats per minute respectively.
The results seen in the ITT population were very similar on both mean diastolic BP (change from baseline to end of treatment; nifedipine GITS −8.9 mm Hg, bendrofluazide −7.7 mm Hg; mean difference between treatments −1.2 mm Hg, one-sided upper 95% confidence limit 0.2 mm Hg) and systolic BP (change from baseline to end of treatment; nifedipine GITS −9.9 mm Hg, bendrofluazide −10.6 mm Hg; mean difference between treatments 0.7 mm Hg, one-sided upper 95% confidence limit 3.4 mm Hg).
Safety
The overall incidence of any adverse event occurring in patients treated with nifedipine GITS was 34.0% (34/100), compared to 29.0% (29/100) treated with bendrofluazide. Those adverse events occurring with an incidence greater than or equal to 3.0% with either treatment are summarised in Table 3 .
The commonest adverse event was headache, arising in 9.0% (9/100) of patients treated with nifedipine GITS, compared to 5.0% (5/100) of patients treated with bendrofluazide. As well as headache, vasodilatation, peripheral oedema, paraesthesia and rhinitis occurred at a greater frequency in patients treated with nifedipine GITS compared to patients treated with bendrolfuazide. Nausea and abdominal pain occurred at a greater frequency in patients treated with bendrofluazide compared to patients treated with nifedipine GITS.
One patient in the bendrofluazide treatment group died during the course of the study, 11 days after a cerebrovascular accident. This was considered by the investigator to be 'possibly' related to the study drug, although it is more likely to have been due to a previous underlying condition.
72 Table 2 Baseline and change from baseline of trough diastolic and systolic blood pressure and heart rate (per-protocol efficacy population) Three serious adverse events were reported during the study. One patient experienced abdominal pain on day 8 of bendrofluazide treatment, necessitating surgical intervention, considered 'not' related to the study drug. One patient suffered a cerebrovascular accident on day 13 of bendrofluazide treatment, as described above. One patient was admitted to hospital for a minor gynaecological procedure 27 days after the last dose of nifedipine GITS 20 mg, considered 'not' related to the study drug.
Other than the patient who died, 10 randomised patients withdrew from the study due to adverse events, five in each treatment group. Events resulting in withdrawal from nifedipine GITS treatment were: anxiety, constipation, anorexia and dyspepsia; facial oedema and vasodilatation; hypokinesia and paraesthesia; somnolence; and headache and somnolence. Events resulting in withdrawal from bendrofluazide treatment were: headache (two patients); abdominal pain; constipation; and diarrhoea.
The frequencies of elevations of blood urea and glucose in patients with values below or within the normal range pre-active treatment, but above the normal range post-active treatment, were higher in the bendrofluazide treatment group (9.6% and 30.4% respectively) than in the nifedipine GITS treatment group (3.1% and 18.8% respectively). The only other notable difference between the two groups was an increased incidence of lymphocytes below the normal range (in patients with high or normal values pre-treatment) in the bendrofluazide treatment group (15.0%) compared to the nifedipine GITS treatment group (5.1%), although this is unlikely to be significant.
Discussion
Nifedipine is a 1.4 dihydropyridine derivative that was first introduced in 1975 in the form of a capsule, taken three times a day. Since then, with more advanced pharmaceutical technology, the dosing interval has been reduced to once daily by means of the GITS tablet. This brings with it not only improved patient convenience, but also near constant plasma nifedipine levels which avoids the peaks and troughs that may be associated with fluctuating blood pressure control and increased incidence of adverse effects.
Although calcium antagonists have been used in the treatment of hypertension for over 20 years, based upon their efficacy and tolerability, recently data have become available to demonstrate that, not only do they reduce BP, but also that they decrease the incidence of cardiovascular events that are the sequelae of hypertension. 2, 3 The present study compared low doses of two widely prescribed classes of antihypertensive agent, namely the calcium antagonist nifedipine, in its long-acting GITS formulation, 20 mg and the thiazide diuretic bendrofluazide 2.5 mg, in the treatment of patients aged 55 to 80 years with mild-to-moderate hypertension.
Both drugs resulted in similar mean BP reductions of 10.4/8.9 mm Hg for nifedipine GITS and 10.5/7.9 mm Hg for bendrofluazide after 6 weeks of treatment, such that nifedipine GITS 20 mg once daily was 'at least equivalent' as bendrofluazide 2.5 mg once daily in the reduction of trough diastolic BP after 6 weeks active treatment, where inequivalence had been predefined as nifedipine GITS being 5 mm Hg or more worse than bendrofluazide 2.5 mg (one-sided upper 95% confidence limit). Nifedipine GITS also demonstrated a similar effect on trough systolic BP and heart rate after 6 weeks treatment.
Both treatments were well tolerated with 10/200 patients (5.0%) withdrawing due to adverse events, five patients in each group. In general, the events concerned were known side effects of the two classes of drug. The overall incidence of adverse events was 34.0% with nifedipine GITS and 29.0% with bendrofluazide. The commoner adverse events reported in this study were as expected with these two classes of drug. An increased incidence of two laboratory abnormalities (elevated urea and glucose) commensurate with a thiazide diuretic were observed in the bendrofluazide treatment group, as were gastrointestinal effects such as nausea, constipation and abdominal pain. Events consequent upon the peripheral vasodilatory properties of nifedipine such as headache, vasodilatation and peripheral oedema predominated in that group.
Nifedipine GITS 20 mg od therefore resulted in a modest but significant reduction in blood pressure, comparable to that observed with bendrofluazide 2.5 mg od. Although no placebo comparison was included, previous studies have shown that nifedipine GITS 20 mg is superior to placebo 1 and suggest it is likely to be less effective than nifedipine GITS 30 mg. 4 However, the incidence of adverse effects was also lower than may be expected with higher doses. 5 Thus the data from this study demonstrates that nifedipine GITS 20 mg once daily is an effective treatment of mild-to-moderate hypertension, being at least equivalent to bendrofluazide 2.5 mg once daily in reducing trough diastolic blood pressure.
